This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on HighWire  • Citing articles on Web of Science (19)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

EDMUND L. DUBOIS, M.D.

AMA Arch Derm. 1955;71(5):570-574.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

The lupus erythematosus cell phenomenon is intimately connected with the pathogenesis and clinical results of therapy of systemic lupus erythematosus. A method has been devised for quantitatively assaying in vitro the effects of various chemicals upon this phenomenon. Detailed observations of the inhibition of lupus erythematosus cell formation by quinacrine (Atabrine) are presented.

Prokoptchouk in 1940 introduced the use of quinacrine in the treatment of lupus erythematosus,¹ and Popoff² reported similar success. Since the recent report in the English literature by Page³ there have been a number of confirmatory studies.^* One of the cases in Page's series had active systemic lupus, which responded well to 200 mg. of quinacrine daily. In view of this and the evidence that systemic lupus erythematosus is a malignant form of the discoid variety, it seemed important to study the use of quinacrine (Mepacrine) in the generalized . . . [Full Text PDF of this Article]

Author Affiliations
Los Angeles

From the Department of Internal Medicine of the University of Southern California Medical School and the Los Angeles County General Hospital.

Footnotes
Atabrine was supplied by J. B. Rice, M.D., of Winthrop-Stearns, Inc., New York.

This study was supported by a grant from the Attending Staff Association fund of the Hospital.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?